BD Biosciences Launches New BD LSRFortessa(TM) Cell Analyzer

SAN JOSE, Calif., April 14 /PRNewswire/ -- Building upon its powerful BD™ LSR cell analyzer platform, BD Biosciences launched today a new off-the-shelf BD LSRFortessa™ System, which uses up to four lasers -- blue, red, violet and UV -- that enable the detection of up to 18 colors simultaneously.

This new system occupies a 30''x 36" benchtop footprint, allowing researchers to maximize utilization of their lab space, without sacrificing system power. The system includes a number of innovative technologies, including novel collection optics that reduce excitation losses and improve light collection efficiency. The result is optical efficiency that delivers maximal sensitivity and resolution for multicolor applications.

"Our quest is to enhance cellular analysis by making multicolor flow cytometry analysis more powerful and accessible to life science researchers," said James Glasscock, President, Cell Analysis, BD Biosciences. "This new BD LSRFortessa System is a perfect example of how we are offering researchers powerful, flexible, high-performance tools that will meet their needs today and tomorrow."

As researchers' needs grow, the new BD LSRFortessa System may be upgraded with additional or new lasers through the special order program to meet their precise assay requirements. This system is complemented by the special order BD LSRFortessa Cell Analyzer, which was launched in June 2009. The special order BD LSRFortessa is customer configurable with up to five lasers, as well as a choice of more than 11 wavelengths, 30 positional choices for detectors, and multiple power options to meet researchers' exact specifications.

The BD LSRFortessa System is the newest addition to the line of BD™ LSR cell analyzers – the preferred tool of life science researchers worldwide working in core, academic, pharmaceutical and biotechnology laboratories.  For more information, please visit: http://www.bdbiosciences.com/instruments/lsr/index.jsp

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

SOURCE BD-Becton Dickinson